龙津药业(002750) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net loss of between 3.6 million and 4.9 million yuan for the first half of 2024, compared to a loss of 15.78 million yuan in the same period last year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be a loss of between 9.7 million and 13.15 million yuan, down from a loss of 19.47 million yuan year-on-year[2]. - Basic earnings per share are projected to be a loss of between 0.0090 yuan and 0.0122 yuan, compared to a loss of 0.0394 yuan in the previous year[2]. - The financial data in the earnings forecast has not been audited by a registered accountant[3]. - The specific financial data will be disclosed in the regular report[5]. Revenue Decline - The decline in revenue is attributed to policy factors such as medical insurance payment restrictions and a 67% price reduction for the company's injectable product, which is part of a centralized procurement program[4]. Cost Management - The company has implemented cost reduction and efficiency enhancement measures, leading to improved production capacity utilization and reduced production costs[4]. - Research and development expenses have decreased as projects gradually enter the capitalization stage[4]. - The company received performance compensation from a committed party, contributing to a reduction in the loss compared to the previous year[4]. Investor Advisory - Investors are advised to make cautious decisions and be aware of investment risks[6].